Navigation Links
Pearl Therapeutics Appoints Howie Rosen to Board of Directors
Date:11/23/2009

REDWOOD CITY, Calif., Nov. 23 /PRNewswire/ -- Pearl Therapeutics Inc., a biopharmaceutical company developing therapeutic products for the treatment of chronic respiratory diseases, today announced the appointment of Howie Rosen to the company's Board of Directors. Mr. Rosen has 25 years of experience in the pharmaceutical and biotechnology industries, including key roles at Gilead Sciences and ALZA Corporation. His appointment increases the number of directors on Pearl's Board to six.

"Howie brings a wealth of product development, commercialization and general management experience to Pearl, having held senior positions at some of the leading companies in the industry," said Perry Karsen, Chief Executive Officer of Pearl Therapeutics. "His proven track record in the drug delivery market will be invaluable to Pearl as we advance our proprietary products toward late-stage development for the treatment of chronic obstructive pulmonary disease."

"I look forward to working with Pearl's Board and management team to help develop and commercialize their very promising products for the treatment of serious, highly prevalent respiratory diseases," said Mr. Rosen. "Because of Pearl's distinctive technology platform, their products have the potential to offer patients and clinicians many compelling advantages over currently available therapies."

Mr. Rosen is currently a consultant to several companies in the industry and a lecturer in the Department of Chemical Engineering at Stanford University. He previously served as Vice President, Commercial Strategy, at Gilead Sciences, Inc., where he was responsible for strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead's overall portfolio and business planning. Prior to Gilead, Mr. Rosen spent more than 10 years in various roles at ALZA Corporation, an operating company within the Johnson & Johnson Family of Companies
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. String of fullerene pearls
3. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
4. MUSCs Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr.
5. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
6. Pearl Therapeutics Secures $8 Million in Debt Financing
7. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... ... Earned Value Management can improve control over clinical development costs, payments, and accruals and ... , ... June 11, 2009 -- ClearTrial ( www.cleartrial.com ), a leading provider of clinical trial ...
... STAAR Surgical Company (Nasdaq: STAA ), a ... products, today announced that the FDA has granted 510(k) ... the Affinity(TM) Collamer(R) Three-Piece NTIOL and the Elastimide(TM) Silicone ... a new era of insertion devices for the company ...
... June 11 New data from Phase 3 ... (NYSE: WYE ) investigational pneumococcal vaccine, Prevenar 13* ... provide coverage against the 13 most prevalent serotypes associated with ... children younger than five worldwide. , , ...
Cached Biology Technology:ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6
(Date:7/10/2014)... 10, 2014) Consuming a whole fresh avocado with ... enhanced provitamin A carotenoid (alpha- and beta-carotene) absorption and ... vitamin A, according to new research (1) published ... , Vitamin A is involved in reproductive health ... and vision; and has antioxidant properties. Provitamin A carotenoids, ...
(Date:7/9/2014)... diseases can occur simultaneously in distinct sites in ... effective for one disorder may exacerbate the other. ... which alleviates joint disease but can worsen periodontal ... of The American Journal of Pathology ... anti-arthritic drugs, specifically DTrp8-ɣMSH (DTrp), that acts via ...
(Date:7/9/2014)... one gene for another in a line of living ... reality within this decade. As with any new technology, ... disease-causing genes in humans, for example--as well as questions ... of those concerns to rest: using gene-editing techniques on ... in the cells. The new results were published July ...
Breaking Biology News(10 mins):New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3
... Rebekah E. Gee MD MPH FACOG, Assistant Professor, LSU ... and Medicine, has been chosen to receive a Recognition ... Leadership Award from the Association of Maternal & Child ... vision, and contributions to the health of women, children, ...
... The University of Michigan,s first human embryonic stem cell line ... registry, making the cells available for federally-funded research. It is ... University of Michigan to be placed on the registry. ... derived in October 2010 from a cluster of about 30 ...
... cues from their rivals the honeybees to learn where the ... Mary, University of London. Writing in the journal ... Biological and Chemical Sciences explain how they trained a colony ... by a different species, the honeybee ( Apis mellifera ), ...
Cached Biology News:LSUHSC's Gee honored for improving health of women, children and families 2U-M human embryonic stem cell line placed on national registry 2U-M human embryonic stem cell line placed on national registry 3Bumblebees get by with a little help from their honeybee rivals 2
...
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
Biology Products: